Development of cell-SELEX technology and its application in cancer diagnosis and therapy

International Journal of Molecular Sciences

Volumn 17, Issue 12, 2016, Pages

  Chen, Man ^a   Yu, Yuanyuan ^a   Jiang, Feng ^a,b   Zhou, Junwei ^a   Li, Yongshu ^a   Liang, Chao ^a   Dang, Lei ^a   Lu, Aiping ^a   Zhang, Ge ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b NINGBO UNIVERSITY   (China)

Author keywords

Aptamer; Cancer; Cell SELEX; Diagnosis; SELEX; Therapy

Indexed keywords

CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; MAGNETIC NANOPARTICLE; MEMBRANE PROTEIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE STRANDED DNA; SINGLE STRANDED RNA; CELL SURFACE RECEPTOR;

3D CELL SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; CANCER CELL LINE; CANCER DIAGNOSIS; CANCER THERAPY; CELL SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; CHEMICAL BINDING; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HYBRID SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; INTERNALIZATION; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TARGET CELL; TECS SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; ANIMAL; CELLS; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; CELLS; HUMANS; NEOPLASMS; RECEPTORS, CELL SURFACE; SELEX APTAMER TECHNIQUE;

EID: 85006100681     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17122079     Document Type: Review

References (80)

1. Ma, H.; Liu, J. Nucleic acid aptamers in cancer research, diagnosis and therapy. Chem. Soc. Rev. 2015, 44, 1240–1256.
2. Song, K.M.; Lee, S. Aptamers and their biological applications. Sensors 2012, 12, 612–631.
3. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505–510.
4. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818–822.
5. Sun, H.; Zhu, X. Oligonucleotide aptamers: New tools for targeted cancer therapy. Mol. Ther. Nucleic Acids 2014, 3, 182.
6. Gopinath, S.C.B. Methods developed for SELEX. Anal. Bioanal. Chem. 2007, 387, 171–182.
7. Morris, K.N.; Jensen, K.B.; Julin, C.M.; Weil, M.; Gold, L. High affinity ligands from in vitro selection: Complex targets. Proc. Natl. Acad. Sci. USA 1998, 95, 2902–2907.
8. Sefah, K.; Shangguan, D.; Xiong, X.; O’Donoghue, M.B.; Tan, W. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5, 1169–1185.
9. Fang, X.H.; Tan, W.H. Aptamers generated from cell-SELEX for molecular medicine: A chemical biology approach. Acc. Chem. Res. 2010, 43, 48–57.
10. Shangguan, D.; Cao, Z.; Meng, L. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 2008, 7, 2133–2139.
11. Guo, K.T.; Ziemer, G.; Paul, A.; Wendel, H.P. CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci. 2008, 9, 668–678.
12. Wu, C.C.; Yates, J.R. The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 2003, 21, 262–267.
13. Mallikaratchy, P.; Tang, Z.; Kwame, S.; Meng, L.; Shangguan, D.; Tan, W. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt’s lymphoma cells. Mol. Cell. Proteom. 2008, 6, 2230–2238.
14. Tang, Z.; Shangguan, D. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 2007, 79, 4900–4907.
15. Raddatz, M.S.; Dolf, A. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed. Engl. 2008, 47, 5190–5193.
16. Avci-Adali, M.; Metzger, M.; Perle, N.; Ziemer, G.; Wendel, H.P. Pitfalls of cell-systematic evolution of ligands by exponential enrichment (SELEX): Existing dead cells during in vitro selection anticipate the enrichment of specific aptamers. Oligonucleotides 2010, 20, 317–323.
17. Cox, J.C.; Rajendran, M.; Riedel, T. Automated acquisition of aptamer sequences. Comb. Chem. High Throughput Screen. 2002, 5, 289–299.
18. Cox, J.C.; Ellington, A.D. Automated selection of anti-Protein aptamers. Biorg. Med. Chem. 2001, 9, 2525–2531.
19. Zhou, J.; Rossi, J. Aptamers as targeted therapeutics: Current potential and challenges. Nat. Rev. Drug Discov. 2016.
20. Darmostuk, M.; Rimpelova, S. Current approaches in SELEX: An update to aptamer selection technology. Biotechnol. Adv. 2015, 33, 1141–1161.
21. Mayer, G.; Ahmed, M.S. Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc. 2010, 5, 1993–2004.
22. Souza, A.G.; Marangoni, K. 3D Cell-SELEX: Development of RNA aptamers as molecular probes for PC-3 tumor cell line. Exp. Cell Res. 2016, 341, 147–156.
23. Bowser, M.T. SELEX: Just another separation. Analyst 2005, 130, 128–130.
24. Kuwahara, M.; Obika, S. In vitro selection of BNA (LNA) aptamers. Artif. DNA 2013, 4, 39–48.
25. Ninomiya, K.; Kaneda, K.; Kawashima, S.; Miyachi, Y.; Ogino, C.; Shimizu, N. Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorg. Med. Chem. Lett. 2013, 23, 1797–1802.
26. Wang, Y.; Luo, Y.; Bing, T. DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. PLoS ONE 2014, 9, e100243.
27. Shigdar, S.; Qiao, L.; Zhou, S.F. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013, 330, 84–95.
28. Chen, C.K.; Kuo, T.L. Subtractive SELEX against two heterogeneous target samples: Numerical simulations and analysis. Comput. Biol. Med. 2007, 37, 750–759.
29. Gyllensten, U.B.; Erlich, H.A. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc. Natl. Acad. Sci. USA 1988, 85, 7652–7656.
30. Dickman, M.; Hornby, D.P. Isolation of single-stranded DNA using denaturing DNA chromatography. Anal. Biochem. 2000, 284, 164–167.
31. Higuchi, R.G.; Ochman, H. Production of single-stranded DNA templates by exonuclease digestion following the polymerase chain reaction. Nucleic Acids Res. 1989, 17, 5865.
32. Liang, C.; Li, D. Comparison of the methods for generating single-stranded DNA in SELEX. Analyst 2015, 140, 3439–3444.
33. Huafang, G.; Shengce, T.; Dong, W. Comparison of different methods for preparing single stranded DNA for oligonucleotide microarray. Anal. Lett. 2003, 13, 2849–2863.
34. Ohuchi, S. Cell-SELEX technology. Biores Open Access 2012, 1, 265–272.
35. Cerchia, L.; Ducongé, F. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 2005, 3, 123.
36. Ohuchi, S.P.; Ohtsu, T.P.; Nakamura, Y. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie 2006, 88, 897–904.
37. Kim, J.W.; Kim, E.Y. Identification of DNA aptamers toward epithelial cell adhesion molecule via cell-SELEX. Mol. Cells 2014, 37, 742–746.
38. Hicke, B.J.; Marion, C. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 2001, 276, 48644–48654.
39. Boltz, A.; Piater, B. Bi-specific aptamers mediating tumor cell lysis. J. Biol. Chem. 2011, 286, 21896–21905.
40. Thiel, W.H.; Thiel, K.W. Cell-internalization SELEX: Method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. Method Mol. Biol. 2015, 1218, 187–199.
41. Thiel, K.W.; Hernandez, L.I. Delivery of chemo-sensitizing siRNAs to her2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012, 40, 6319–6337.
42. Huang, Y.Z.; Hernandez, F.J. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol. Pharmacol. 2012, 82, 623–635.
43. Shangguan, D.; Li, Y. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 2006, 103, 11838–11843.
44. Sefah, K.; Meng, L.; Lopezcolon, D. DNA aptamers as molecular probes for colorectal cancer study. PLoS ONE 2010, 5, e14269.
45. Bamrungsap, S.; Chen, T.; Shukoor, M.I. Pattern recognition of cancer cells using aptamer-conjugated magnetic nanoparticles. ACS Nano 2012, 6, 3974–3981.
46. Hicke, B.J.; Stephens, A.W.T. Tumor targeting by an aptamer. Nucl. Med. 2006, 47, 668–678.
47. Girvan, A.C.; Teng, Y.; Casson, L.K. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther. 2006, 5, 1790–1799.
48. Ferreira, C.S.M.; Matthews, C.S.; Missailidis, S. DNA aptamers that bind to MUC1 tumour marker: Design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol. 2006, 7, 289–301.
49. Kang, W.J.; Chae, J.R.; Cho, Y.L.; Lee, J.; Kim, S. Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small 2009, 22, 2519–2522.
50. Hung, M.C.; Matin, A.; Zhang, Y. HER-2/NEU-targeting gene therapy—A review. Gene 1995, 159, 65–71.
51. Niazi, J.H.; Verma, S.K. In vitro HER2 protein-induced affinity dissociation of carbon nanotube-wrapped anti-HER2 aptamers for HER2 protein detection. Analyst 2015, 140, 243–249.
52. Rudge, J.S.; Holash, J. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad. Sci. USA 2007, 104, 18363–18370.
53. Zhang, Z.; Schluesener, H.J. Pigpen is a cellular binding protein of therapeutic oligonucleotides. Cytotherapy 2005, 7, 186–194.
54. Mhawech-Fauceglia, P.; Zhang, S.; Terracciano, L. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology 2007, 50, 472–483.
55. Zwick, E.; Bange, J. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 2001, 8, 161–173.
56. Zhang, Y.; Chen, Y.; Han, D.; Ocsoy, I.; Tan, W. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010, 2, 907–918.
57. Lupold, S.E.; Hicke, B.J. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002, 62, 4029–4033.
58. Farokhzad, O.C.; Jon, S. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cell. Cancer Res. 2004, 64, 7668–7672.
59. Farokhzad, O.C.; Cheng, J. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 6315–6320.
60. Taghdisi, S.M.; Danesh, N.M. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. J. Drug Target 2013, 21, 739–744.
61. Wu, X.; Chen, J.; Wu, M. Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics. 2015, 5, 322–344.
62. Bates, P.J.; Laber, D.A.; Miller, D.M.; Thomas, S.D.; Trent, J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009, 86, 151–164.
63. Rosenberg, J.E.; Bambury, R.M. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investig. New Drug 2014, 32, 178–187.
64. Lu, M.; Zhou, L.; Zheng, X. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method. Cancer Biomark. 2015, 15, 163–170.
65. Mallikaratchy, P.; Tang, Z.; Kwame, S. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy Mu chain in Burkitt′s lymphoma cells. Mol. Cell. Proteom. 2007, 6, 2230–2238.
66. Ferreira, C.S.M.; Cheung, M.C. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009, 37, 866–876.
67. Cerchia, L.; Esposito, C.L.; Jacobs, A.H. Differential SELEX in human glioma cell lines. PLoS ONE 2009, 4, 7971.
68. Cerchia, L.; Esposito, C.L. Targeting Axl with a high-affinity inhibitory aptamer. Mol. Ther. 2012, 20, 2291–2303.
69. Dastjerdi, K.; Tabar, G.H. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol. Appl. Biochem. 2011, 58, 226–230.
70. Shigdar, S.; Lin, J. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011, 102, 991–998.
71. Subramanian, N.; Kanwar, J.R. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. J. Biomed. Sci. 2015, 22, 4.
72. Dua, P.; Kang, H.S.; Hong, S.M.; Tsao, M.S.; Kim, S.; Lee, D.K. Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein. Cancer Res. 2013, 73, 1934–1945.
73. Zhou, J.; Satheesan, S. Cell-Specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem. Biol. 2015, 22, 379–390.
74. Rong, Y.; Chen, H.; Zhou, X.F. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers. Oncotarget 2016, 7, 8282–8294.
75. Soldevilla, M.M.; Villanueva, H. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells. Oncotarget 2016, 7, 23182–23196.
76. Zhu, H.; Li, J. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy. Chem. Med. Chem. 2015, 10, 39–45.
77. Mayer, G. The chemical biology of aptamers. Angew. Chem. Int. Ed. 2009, 48, 2672–2689.
78. Oney, S.; Lam, R.T.S. Development of universal antidotes to control aptamer activity. Nat. Med. 2009, 15, 1224–1228.
79. Ye, M.; Hu, J.; Peng, M. Generating aptamers by cell-SELEX for applications in molecular medicine. Int. J. Mol. Sci. 2012, 13, 3341–3353.
80. Hwang, D.W.; Ko, H.Y. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med. 2010, 51, 98–105.